ADVB: Advanced Biomed Inc Market Cap to Revenue Ratio

Corporate company logo of Advanced Biomed Corp (ADVB)

The EV/Revenue multiple demonstrates the capitalization dynamics of Advanced Biomed Inc (ADVB), where the 0.00 mark reflects the latest data. The business relies on microfluidic chips and cloud software for tumor screening. A strong team of engineers and laboratory technicians is leading the development of diagnostic systems. Currently, Advanced Biomed Inc (ADVB) is scaling the accuracy of liquid biopsies and undergoing certification in the Asian region.

advanbiomed.com - ADVB P/S Multiple (period 03/07/2025 - 03/07/2025)

Analytical breakdowns for Advanced Biomed Inc (ADVB)

- stock value and consensus price forecast:
Stock Price advanbiomed.com|ADVB - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Advanced Biomed Corp|ADVB - Real Price to Acquire Entire Company
- business book valuation details:
Net Assets per Single Share Advanced Biomed|ADVB - Book Capitalization|Market Capitalization to Book Value Ratio advanbiomed.com|ADVB - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Ratio Advanced Biomed Inc|ADVB - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio advanbiomed.com|ADVB - Company Aggregate Debts|Debts to Book Value Advanced Biomed Corp|ADVB - Company Long-Term Debts|Company Short-Term Indebtedness Advanced Biomed|Intermediate Coverage Ratio advanbiomed.com
- financial results and valuation multiples details:
ADVB - Net Profit|Expected Profit Advanced Biomed Inc|ADVB - P/E Multiple|Market Cap to Projected Earnings advanbiomed.com|ADVB - Price/Earnings to Growth Ratio|Company Value to EBITDA Advanced Biomed Corp|ADVB - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Advanced Biomed|ADVB - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months advanbiomed.com|ADVB - Earnings growth in current year|Projected earnings per share growth rate for next year Advanced Biomed Inc
- issuer revenue and sales details:
ADVB - Company Sales|Company Future Revenue advanbiomed.com|ADVB - P/S Multiple|Market Cap to Expected Sales Ratio Advanced Biomed Corp
General company analysis:ADVB - Advanced Biomed Inc.
Manufactured products of Advanced Biomed

Assessing the long-term risks of Advanced Biomed Inc (ADVB) requires an analysis of the market capitalization to annual sales ratio. This coefficient determines the multiple an investor pays per unit of revenue, capturing the real-time assessment of quotes in response to microeconomic changes. The trend of the company's rolling P/S allows for the tracking of phases of market optimism or asset overvaluation. For a microfluidic platform business, this indicator reflects the monetization potential of consumables, which serve as a steady cash generator.

Competing companies

P/S Multiple beigene.com (ONC)|P/S Multiple HALO (Halozyme)|RVMD: Market Cap to Revenue Ratio|AAPG: Market Cap to Revenue|CGON: Price-to-Revenue Ratio|URGN: P/S Multiple|bicara.com (BCAX) - P/S Multiple|Price-to-Revenue Ratio Personalis|Market Cap to Revenue Ratio ERAS (Erasca Inc)|P/S Multiple DCTH|Market Cap to Revenue Y-mAbs Corp YMAB|P/S Multiple AURA (Aura Biosciences, Inc.)|Candel Therapeutics Inc. (CADL) - Price to Sales|Accuray - P/S Multiple|SLS (SELLAS Life Sciences) - Market Cap to Revenue Ratio|ACTU (Actuate Therapeutics, Inc) - Market Cap to Revenue|Citius Oncology Inc - Market Capitalization-to-Revenue Ratio|HURA (TuHURA Biosciences Inc.) - P/S Multiple|Price-to-Revenue Ratio TARA|P/S Multiple FATE|Price-to-Revenue Coefficient aadibio.com|Price-to-Revenue Ratio TScan Therapeutics, Inc. TCRX|Champions Oncology Inc (CSBR) - Price to Sales|XBIT - Price-to-Revenue Ratio|CEL-SCI Corporation (CVM) - Market Cap to Revenue|OSTX: P/S Multiple|Price to Sales radiopharmtheranostics.com (RADX)|ARTV (Artiva Biotherapeutics Inc.) - P/S Multiple|Market Cap to Revenue Ratio ANL (Adlai Nortye Limited)|Market Cap to Revenue VERU (Veru Inc.)|TPST (tempesttx.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple XLO (Xilio Therapeutics)|Price-to-Revenue Coefficient Renovaro Biosciences (RENB)|MURA - Price-to-Revenue Ratio|KAPA (Kairos Pharma Ltd) - Market Cap to Revenue Ratio|OKUR: P/S Multiple|Market Cap to Revenue CytoMed Therapeutics Limited|CRIS (Curis Inc.) - P/S Multiple|P/S Multiple Apollomics Corp|P/S Multiple THAR|Genprex Inc - Market Cap to Revenue Ratio|Calidi Biotherapeutics, Inc. - Market Cap to Revenue|sunshinebiopharma.com - Price-to-Revenue Ratio|Xenetic Bio - P/S Multiple|SLRX: Price-to-Revenue Ratio|PPBT: P/S Multiple|Market Cap to Revenue American Oncology Network, Inc.|BGNE (BeiGene, Ltd.) - P/S Multiple|P/S Multiple checkpointtx.com|Price-to-Revenue Ratio Elevation Oncology (ELEV)|icadmed.com - Market Cap to Revenue Ratio|P/S Multiple IKNA (Ikena Oncology)|NTBL - Market Cap to Revenue|Viracta - P/S Multiple|Price to Sales morphosys.com|NAYA Biosciences Inc. (NAYA) - Price-to-Revenue Ratio|Ascentage Pharma Group International - Market Capitalization-to-Revenue Ratio